Summary
The Food and Drug Administration (FDA) is seeking a cooperative agreement (U01 mechanism) to support a human abuse potential (HAP) study of botanical kratom. This is a clinical trial-required opportunity, meaning the awardee must conduct a formal clinical trial examining the abuse potential of kratom in human subjects. The study is intended to generate scientific evidence to inform FDA's regulatory understanding of kratom's pharmacological and behavioral effects. This is a forecasted opportunity, meaning it has not yet been formally solicited.